Allogene Therapeutics, Inc. short interest in 2026
In 2026, Allogene Therapeutics, Inc.'s disclosed short interest ran from 8.29% of shares outstanding on 15 Jan 2026 to 17.25% on 15 Sep 2026, a change of +8.96 percentage points. The year's high was 26.00% on 30 Jun 2026 and its low 8.29% on 15 Jan 2026, averaging 15.97% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 12.15 days on 31 Aug 2026. Full history: Allogene Therapeutics, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 8.29% (15 Jan 2026)
- End of year
- 17.25% (15 Sep 2026)
- Change
- +8.96 pp
- High
- 26.00% (30 Jun 2026)
- Low
- 8.29% (15 Jan 2026)
- Average
- 15.97%
- Highest days to cover
- 12.15 (31 Aug 2026)
- SEC filings marked
- 6
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 8.29% | 3.51 | |
| 30 Jan 2026 | 8.37% | 2.59 | |
| 13 Feb 2026 | 8.88% | 3.74 | |
| 27 Feb 2026 | 10.65% | 3.96 | |
| 13 Mar 2026 | 10.02% | 6.21 | 10-K filed, results (8-K) |
| 31 Mar 2026 | 13.15% | 4.81 | |
| 15 Apr 2026 | 14.92% | 1.60 | |
| 30 Apr 2026 | 15.12% | 3.71 | |
| 15 May 2026 | 17.34% | 6.41 | 10-Q filed, results (8-K) |
| 29 May 2026 | 18.25% | 6.77 | |
| 15 Jun 2026 | 19.70% | 6.21 | |
| 30 Jun 2026 | 26.00% | 5.14 | |
| 15 Jul 2026 | 24.49% | 6.35 | |
| 31 Jul 2026 | 24.92% | 9.23 | |
| 14 Aug 2026 | 17.06% | 11.93 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 17.11% | 12.15 | |
| 15 Sep 2026 | 17.25% | 11.26 |
See also: Allogene Therapeutics, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.